Vesalius Longevity Labs Announces Commencement of Trading on the Canadian Securities Exchange Under the Symbol "VLAB"

VANCOUVER, BC and SCOTTSDALE, Ariz., Nov. 10, 2026 /CNW/ -- Vesalius Longevity Labs Inc. (formerly Sweet Earth Holdings Corporation) ("Vesalius" or the "Company") (CSE: SE) (to trade as "VLAB") is pleased to announce that, further to its news releases dated March 4, 2025, June 18, 2025, February 6, 2026, March 11, 2026, September 3, 2026 and October 29, 2026, the Company will commence trading on the Canadian Securities Exchange ("CSE") under the symbol "VLAB" on November 12, 2026.

Additional information on the Company and the business of Vesalius can be found in the Company's Listing Statement dated November 9, 2026 as filed on SEDAR+ at www.sedarplus.ca.

About Vesalius

Vesalius Longevity Labs (CSE: VLAB), is a longevity science and regenerative health platform focused on being the trusted seed-to-brand partner across the consumer journey for peptide therapeutics, biologics and preventative healthcare. Vesalius operates a scalable B2Doctor2Consumer ecosystem designed to support healthcare providers and telehealth infrastructure.  Vesalius will manufacture under its Peptual® brand "Made-in-the-USA" peptide APIs (active pharmaceutical ingredients) for domestic and international compounding supply chains.  Vesalius's expanding ecosystem includes regenerative medicine, multi-faceted compounding pharmacy initiatives, biologics partnerships and advanced AI-powered technologies designed to support the future of personalized health and wellness.

Investors interested in learning more about Vesalius Longevity Labs are encouraged to contact the Company at: https://www.vesaliuslabs.com/

For further information, please refer to the Company's disclosure record on SEDAR+ at www.sedarplus.ca.

On Behalf of the Company

"Pradeep Albert"

Chief Executive Officer

The CSE has neither approved nor disapproved the contents of this press release.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur and specifically include statements regarding the Company's strategies, expectations, planned operations or future actions; final approval from the CSE; and re-commencement of trading of the Company Shares and timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Vesalius Longevity Labs Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2026/10/c4265.html